8-K: 180 Life Sciences Rebrands to ETHZilla, Raises $4.5M

180 Life Sciences Corp. announced a corporate name change to ETHZilla Corporation, a new Nasdaq ticker, and the exercise of warrants generating over $4.5 million in cash.

Summary

• 180 Life Sciences Corp. is changing its corporate name to ETHZilla Corporation, effective August 18, 2025, at 12:01 a.m. Eastern Standard Time.
• The company's Nasdaq trading symbol for common stock will change from ATNF to ETHZ, and for public warrants from ATNFW to ETHZW, effective at market open on August 18, 2025.
• A new corporate website, www.ETHZilla.com, has been launched in connection with the name change, which will host investor relations information and SEC filings.
• Between August 8, 2025, and August 13, 2025, warrant holders exercised warrants to purchase a total of 2,439,635 shares of common stock for cash.
• These warrant exercises generated approximately $4,522,068.95 in cash proceeds for the company.
• The warrant exercises occurred at various exercise prices: 1,335,862 shares at $1.50 per share, 1,074,250 shares at $2.28 per share, and 4,523 shares at $2.65 per share.
• The exercise of these warrants was exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as they did not involve a public offering and the holders were accredited investors.
• The resale of the shares issued upon exercise of these warrants has been registered under the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant cash inflow from warrant exercises. However, the implied strategic pivot to a new industry (blockchain/crypto) introduces considerable uncertainty, as no details on the new business model or financial projections were provided, balancing the overall sentiment.

Positives

• The company received approximately $4,522,068.95 in cash from the exercise of warrants, strengthening its financial position.
• The name change and new ticker symbols streamline the company's identity, potentially aligning it with a new strategic direction.

Negatives

• The exercise of warrants results in dilution for existing shareholders due to the issuance of new common stock.

Risks

• No new specific business risks were disclosed in this filing.

Future Outlook

The company's name change to ETHZilla Corporation and the launch of a new website strongly suggest a strategic pivot towards a new business focus, likely in the blockchain or cryptocurrency space, moving away from its previous 'Life Sciences' identity. No specific financial guidance or forward-looking statements regarding this new direction were provided.

Industry Context

The rebranding from '180 Life Sciences Corp.' to 'ETHZilla Corporation' and the change in ticker symbols from ATNF/ATNFW to ETHZ/ETHZW indicate a significant strategic shift, likely from the biotechnology/life sciences sector to the blockchain, cryptocurrency, or Web3 industry. This move aligns with a broader trend of companies pivoting to capitalize on emerging technologies, though it represents a complete departure from the company's original stated focus.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares due to warrant exercises. Face a significant strategic shift in the company's business focus, which may alter investment thesis.
• Warrant Holders: Successfully exercised their warrants for cash, converting their rights into common stock.

Next Steps

• The corporate name change to ETHZilla Corporation will become effective at 12:01 a.m. on August 18, 2025.
• The Nasdaq trading symbols for common stock and public warrants will change to ETHZ and ETHZW, respectively, at market open on August 18, 2025.
• The Third Amended and Restated Bylaws will become effective immediately after the name change on August 18, 2025.

Key Dates

Recommendation

The filing indicates a significant strategic pivot from life sciences to a new, implied blockchain/crypto focus, accompanied by a substantial capital raise from warrant exercises. While the cash inflow is positive, the lack of detailed information on the new business model, its operational plans, and financial projections creates considerable uncertainty. Investors should hold existing positions and await further clarity on the company's new strategic direction and its potential for future growth and profitability before making new investment decisions.

Keywords

ETHZilla, 180 Life Sciences, Warrants, Name Change, Corporate Rebranding, Nasdaq, Equity Issuance, Capital Raise, ATNF, ETHZ, Biotechnology, Blockchain